SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

RECK RICHARD A

(Last)

(First)

(Middle)

1440 DAVEY ROAD

(Street)

WOODRIDGE

60517

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Advanced Life Sciences Holdings, Inc. [ ADLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2010

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/07/2010		P⁽¹⁾⁽²⁾		1,190,000	A	$0.042	1,290,000	I	1,270,000 By Self as Trustee of Richard A Reck Trust; 20,000 by Self as Trustee of Daniel Reck Trus

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock Warrant	$0.042	07/07/2010		P⁽¹⁾⁽²⁾		1,190,000		01/07/2011	07/07/2015	Common Stock	1,190,000	$0	1,190,000	I	By Self as Trustee of the Richad A Reck Trust
Unit Warrant	$4.2	07/07/2010		P⁽¹⁾⁽²⁾		11,900		⁽¹⁾⁽²⁾	⁽¹⁾⁽²⁾	Units⁽³⁾	11,900	$0	11,900	I	By Self as Trustee of the Richard A. Reck Trust

Explanation of Responses:

1. On July 7, 2010, Mr. Reck purchased at a price of $4.20 per unti, 11,900 units consisting of, in the aggregate, (i) 1,190,000 shares of the Company's common stock, (ii) warrants to purchsae 1,190,000 shares of common stock at an exercise price of $0.042 per share (the "Stock Warrants") and (iii) warrants to purchase an additional 11, 900 units, with each unit consisting of 100 shares of common stock and 100 Stock Warrants, at an exercise price of $4.20 per additional unit (the "Unit Warrants".

2. The Stock Warrants may be exercised at any time during the period commening six months after the closing date and ending on the fifth anniversary of the closing date. The Unit Warrants may be exercised at any time during the period commencing on the closing date and ending on the earlier of: (i) the date that is 45 days after the Company's first public announcement that the FDA has accepted the Company's Special Protocol Assessment relating to the additional clinical data needed for regulatory approval in the treatment of community acquired bacterial pneumonia and (ii) December 31, 2010.

3. Each Unit consists of 100 shares of common stock and 100 Stock Warrants.

	/s/ Patrick W. Flavin, by power of attorney	07/09/2010
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.